API | calaspargase pegol

calaspargase pegol (Asparlas) Report issue

Biologics Recombinant protein Approved ^FDA

AACT Drugs@FDA MeSH

Active Ingredient History

NOW

Calaspargase pegol, sold under the brand name Asparlas, is a medication for the treatment of acute lymphoblastic leukemia (ALL). It is approved in the United States as a component of a multi-agent chemotherapeutic regimen for ALL in pediatric and young adult patients aged one month to 21 years. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
calaspargase pegol

More Chemistry

Pharmacology

Mechanism of Action:
- L-asparaginase (Erwinia chrysanthemi) ^UniProt
Multi-specific: No
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

Drug Pricing (per unit)

United States

$3666.3320 - $4727.6380

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

calaspargase pegol | calaspargase pegol-mknl | sc-peg asparaginase

Organizations (14)

Research & Development (14)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (9)

Approved Indications (1)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (approved 2018)

Experimental Indications - Clinical Trial Phases 1-4 (9)

Leukemia (Phase 3)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 3)

Leukemia, Myeloid, Acute (Phase 1)

Lymphoma (Phase 1)

Lymphoma, T-Cell, Peripheral (Early Phase 1)

Myelodysplastic Syndromes (Phase 1)

Pancreatic Neoplasms (Phase 1)

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Phase 3)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 11
# of Trial Organizations: 14

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue